Laparoscopic vs open D2 gastrectomy for locally advanced gastric cancer: A meta-analysis

Figure 1 Flow chart of the identification and inclusion of studies. Studies evaluating laparoscopic gastrectomy with D2 (LGD2) were identified to evaluate the procedure as an acceptable alternative to open gastrectomy with D2 (OGD2) for locally advanced gastric cancer (AGC); EGC: Early gastric cancer; RCT: Randomized controlled trial.

Figure 2 Meta-analyses of procedure characteristics. A: Weighted mean operative time; B: Intraoperative blood loss. LGD2: Laparoscopic gastrectomy with D2 extended lymph node dissection; OGD2: Open gastrectomy with D2 extended lymph node dissection; RCT: Randomized controlled trial.

Figure 3 Meta-analyses of patient characteristics. A: Analgesic consumption; B: Time to first ambulation; C: Time to first flatus; D: Time to first oral intake. LGD2: Laparoscopic gastrectomy with D2 extended lymph node dissection; OGD2: Open gastrectomy with D2 extended lymph node dissection; RCT: Randomized controlled trial.

Figure 4 Meta-analyses of postoperative events. A: Postoperative hospitalization; B: Morbidity; C: Reoperation; D: Mortality. LGD2: Laparoscopic gastrectomy with D2 extended lymph node dissection; OGD2: Open gastrectomy with D2 extended lymph node dissection; RCT: Randomized controlled trial.

Figure 5 Meta-analyses of lymph node harvest and tumor recurrence. A: Lymph nodes harvested; B: Tumor recurrence and metastasis. LGD2: Laparoscopic gastrectomy with D2 extended lymph node dissection; OGD2: Open gastrectomy with D2 extended lymph node dissection; RCT: Randomized controlled trial.

Figure 6 Meta-analyses of treatment outcomes between laparoscopic and open D2 gastrectomy. A: Three-year disease-free survival; B: Five-year disease-free survival; C: Three-year overall survival; D: Five-year overall survival. LGD2: Laparoscopic gastrectomy with D2 extended lymph node dissection; OGD2: Open gastrectomy with D2 extended lymph node dissection.